Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Isoniazid
Drug ID BADD_D01204
Description Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
Indications and Usage For the treatment of all forms of tuberculosis in which organisms are susceptible.
Marketing Status approved; investigational
ATC Code J04AC01
DrugBank ID DB00951
KEGG ID D00346
MeSH ID D007538
PubChem ID 3767
TTD Drug ID D09XQF
NDC Product Code 60687-553; 0555-0071; 71610-395; 83112-071; 50090-0410; 63187-978; 0555-0066; 68788-9405; 71610-108; 12785-0003; 50090-0370; 70518-0096; 70518-2576; 43063-463; 62135-550; 0781-3056; 12785-0002; 66639-914; 51079-083; 43367-0100; 71052-611; 46287-009; 71335-0275; 53002-2920
UNII V83O1VOZ8L
Synonyms Isoniazid | Isonicotinic Acid Hydrazide | Hydrazide, Isonicotinic Acid | Phthivazide | Phthivazid | Isonicotinic Acid Vanillylidenehydrazide | Acid Vanillylidenehydrazide, Isonicotinic | Vanillylidenehydrazide, Isonicotinic Acid | Ftivazide | Tubazide | Isonex
Chemical Information
Molecular Formula C6H7N3O
CAS Registry Number 54-85-3
SMILES C1=CN=CC=C1C(=O)NN
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperkalaemia14.05.03.0010.008339%
Hyperkinesia17.01.02.008--Not Available
Hyperpyrexia08.05.02.002--Not Available
Hypersensitivity10.01.03.003--
Hypersensitivity vasculitis24.12.04.013; 23.06.02.005; 10.02.02.017; 01.01.04.0080.005560%Not Available
Hypertonia17.05.02.001; 15.05.04.0070.002780%Not Available
Hyperuricaemia14.09.01.0030.002780%
Hyperventilation19.01.02.004; 22.02.01.006--Not Available
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypoglycaemia14.06.03.001; 05.06.03.0010.002780%
Hypokalaemia14.05.03.0020.005560%
Hypotonia17.05.02.002; 15.05.04.0080.002780%Not Available
Hypouricaemia14.09.01.0060.004170%Not Available
Immune system disorder10.02.01.0010.006949%Not Available
Increased appetite08.01.09.027; 14.03.01.003--Not Available
Influenza like illness08.01.03.010--
Interstitial lung disease22.01.02.003; 10.02.01.0330.004170%Not Available
Irritability19.04.02.013; 08.01.03.011--
Jarisch-Herxheimer reaction10.02.01.0020.002780%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.090898%Not Available
Lactic acidosis14.01.01.0020.011119%Not Available
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.0030.006949%
Leukocytosis01.02.01.0020.009729%
Leukopenia01.02.02.001--Not Available
Libido decreased21.03.02.005; 19.08.03.001--
Liver disorder09.01.08.0010.008895%Not Available
Liver function test abnormal13.03.04.030--Not Available
Liver transplant rejection12.02.03.011; 10.02.03.005; 09.01.08.0070.002780%Not Available
Loss of consciousness17.02.04.0040.019458%Not Available
Lymphadenopathy01.09.01.0020.004170%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene